🔥 BioNTech Made Its Fortune on COVID. Now It's Spending €16.2 Billion to Beat Cancer.

Five years ago, BioNTech was the company that helped end the lockdowns. This week, it told the world that chapter is basically closing — and showed you the war chest it’s taking into the next one.

Let’s get the number on the table first: €16.2 billion. That’s how much cash and investments BioNTech was sitting on at the end of September, even as its revenue kept sliding (BioNTech Q3 release). The COVID windfall didn’t disappear. It got repackaged into a bet on oncology.

Third-quarter revenue came in at €1,289.2 million, down from €1,518.9 million a year earlier — a drop the company pins squarely on “expected lower market demand for BioNTech’s COVID-19 vaccines” (SEC 6-K filing). The vaccine that made BioNTech a household name is now a shrinking seasonal business, and everyone involved knows it.

Here’s the thesis: BioNTech is deliberately trading a declining cash cow for a shot at becoming a cancer company, and for one quarter at least, the math is holding.

🧠 Why This Matters

Most companies that lose a blockbuster product spend years in slow decline. BioNTech is trying to skip that fate by spending the blockbuster’s profits before they run out.

The pivot isn’t subtle. IFRS R&D expenses jumped to €748.1 million in the quarter, up from €564.8 million a year ago — while sales fell. When your top line drops and your research bill climbs by a third at the same time, that’s not drift. That’s a company pointing its balance sheet at a new target on purpose.

And unlike a lot of the AI-era spending stories you’ve been reading, BioNTech is paying for this out of money it already has. No fresh €10 billion debt raise, no dilutive mega-round. Just a very large pile of euros and a decision about where to point it.

📊 Deep Dive

The quarter itself was better than the falling revenue line suggests. BioNTech actually swung to a profit:

• Revenue: €1,289.2M in Q3, vs €1,518.9M a year earlier — down roughly 15%
• IFRS net profit: €184.5M, versus a €28.7M net loss in the same quarter of 2025
• R&D spend: €748.1M (IFRS), up from €564.8M — rising even as sales fell
• Cash and investments: €16,163.8M as of September 30, including €10.2B in straight cash
• Full-year guidance: raised to €1.7–1.9 billion, nudging up the bottom of the range

The engine of the new strategy is a drug called pumitamig (you may have seen it as BNT327), a bispecific antibody BioNTech is developing with Bristol Myers Squibb. It’s in seven pivotal trials under a program BioNTech calls ROSETTA, and a first global Phase 3 study pairing it with Gilead’s sacituzumab govitecan in first-line triple-negative breast cancer is pending regulatory sign-off (SEC 6-K filing).

There was real clinical news underneath the accounting, too. In September, stage 1 data from a Phase 3 trial of gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small-cell lung cancer (BioNTech Q3 release). That’s the kind of result that turns a pipeline slide into a product.

“BioNTech is well positioned for its next phase of growth.” — Ugur Sahin, CEO, BioNTech

⚠️ The Catch

Cancer drugs are where confident pipelines go to get humbled, and BioNTech’s own quarter proves it.

In October, the BNT113 trial in head and neck cancer missed one of its dual primary endpoints. BioNTech also began an early termination of a Phase 2 study of autogene cevumeran in colorectal cancer. And a Phase 3 breast-cancer readout for trastuzumab pamirtecan technically hit its endpoint but with a benefit the company itself called modest — alongside a higher rate of a serious lung side effect.

So the oncology story is genuinely mixed: one near-doubling of survival, one clean miss, one early stop, one muddy win. That’s normal for drug development, but it’s a long way from the near-perfect efficacy BioNTech’s COVID shot delivered in 2020. The year-to-date picture is still a net loss of €1,168.2 million on an IFRS basis, inflated by write-downs on programs the company has decided aren’t core.

Translation: the pivot is funded, but it is very much unproven.

🎯 What Happens Next

Watch the cost line as much as the pipeline. Starting January 1, 2027, BioNTech’s collaboration with Roche and Genentech shifts future R&D costs for a key program largely onto Roche, with BioNTech taking royalties instead (BioNTech Q3 release). That’s a quiet way to keep spending on cancer without the spending showing up entirely on your own books.

Meanwhile, the company is handing cash back to shareholders. Under a buyback of up to $1.0 billion running through May 2027, it had already repurchased 5,037,452 ADSs for $463.3 million by the end of September. Full-year results land March 2, 2027, and the pumitamig Phase 3 approvals are the milestone that will tell you whether ROSETTA is a franchise or a line item.

🧩 Bigger Picture

BioNTech is the clearest test case for a question the whole vaccine industry is quietly asking: what do you do after the pandemic that made you?

The honest answer here is that you take the money and go hunting for the next hard problem. Oncology is a brutally competitive field — Merck’s Keytruda alone is a cancer empire — but it’s also enormous, durable, and nothing like a seasonal vaccine that the market can simply stop buying. BioNTech’s mRNA platform was always pitched as a cancer tool first; COVID was the detour that paid for the lab.

With €16.2 billion in the bank, BioNTech has bought itself something most biotechs never get: the right to be wrong several times before it has to be right once.

“We return capital to shareholders through our share repurchase program.” — Ramón Zapata, CFO, BioNTech

The vaccine era made BioNTech rich. The cancer era will decide whether it stays a drugmaker or becomes a historical footnote with a very healthy savings account.

---

Sources

• BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update — BioNTech
• BioNTech SE Form 6-K, Q3 2026 — U.S. Securities and Exchange Commission

❓ Quick answers

How much revenue did BioNTech report in Q3 2026?

BioNTech reported Q3 2026 revenue of EUR 1,289.2 million on November 3, 2026, down from EUR 1,518.9 million a year earlier, per its earnings release and SEC 6-K filing.

How much cash does BioNTech have?

As of September 30, 2026, BioNTech held EUR 16.2 billion in cash and investments, including EUR 10.2 billion in cash and cash equivalents, according to its SEC 6-K filing.

What is BioNTech's lead cancer drug?

Its lead oncology candidate is pumitamig (BNT327), a bispecific antibody developed with Bristol Myers Squibb and in seven pivotal trials, as stated in its November 3, 2026 update.